Inventor · disambiguated record
Sean Higgins
Also filed as: HIGGINS SEAN · HIGGINS SEAN A
6 granted patents·20 pending applications·39 citations·filing 2019–2024
82Inventor score
Top patents by PatentIndex Score
26 records- 0194US11560555B2Engineered proteinsSCRIBE THERAPEUTICS INC·Filed 2021·Granted Jan 24, 2023·15 cites·25 claims
- 0293US12084692B2Guide scaffoldsSCRIBE THERAPEUTICS INC·Filed 2022·Granted Sep 10, 2024·5 cites·38 claims
- 0393US11535835B1Compositions and methods for the targeting of rhodopsinSCRIBE THERAPEUTICS INC·Filed 2021·Granted Dec 27, 2022·7 cites·26 claims
- 0492US11613742B2Compositions and methods for the targeting of SOD1SCRIBE THERAPEUTICS INC·Filed 2021·Granted Mar 28, 2023·4 cites·25 claims
- 0591US12163125B2Engineered class 2 type V CRISPR systemsSCRIBE THERAPEUTICS INC·Filed 2022·Granted Dec 10, 2024·5 cites·28 claims
- 0688US11976277B2Particle delivery systemsSCRIBE THERAPEUTICS INC·Filed 2023·Granted May 7, 2024·3 cites·23 claims
- 0785US2025136962A1Catalytically dead engineered proteinsSCRIBE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0884US2025043262A1Gene editing pairsSCRIBE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0980US2025011756A1Methods of editing with engineered class 2 type v crispr systemsSCRIBE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1074US2024101984A1Compositions and methods for the targeting of sod1SCRIBE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1174US2022220508A1Engineered casx systemsSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1270US2024026385A1Engineered class 2 type v crispr systemsSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1364US2024392271A1Engineered casx repressor systemsSCRIBE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1464US2024360474A1Self-inactivating vectors for gene editingSCRIBE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1563US2022348925A1Compositions and methods for the targeting of sod1SCRIBE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1661US2025361525A1Aav vectors for gene editingSCRIBE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1760US2024309344A1COMPOSITIONS AND METHODS FOR THE TARGETING OF C9orf72SCRIBE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1860US2023033866A1Compositions and methods for the targeting of rhodopsinSCRIBE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1959US2023032369A1Compositions and methods for the targeting of httSCRIBE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2059US2025333767A1Engineered class 2 type v crispr systemsSCRIBE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2157US2022177872A1Deep mutational evolution of biomoleculesSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2257US2024026386A1Compositions and methods for the targeting of bcl11aSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2355US2024100185A1Compositions and methods for the targeting of ptbp1SCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2453US2023167424A1Compositions and methods for the targeting of pcsk9SCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2552US2024033377A1Aav vectors for gene editingSCRIBE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2649US2021269782A1Rna-guided effector proteins and methods of use thereofUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sean Higgins files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →